A detailed history of Privium Fund Management B.V. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 120,000 shares of TSHA stock, worth $211,200. This represents 0.06% of its overall portfolio holdings.

Number of Shares
120,000
Previous 98,500 21.83%
Holding current value
$211,200
Previous $220,000 9.55%
% of portfolio
0.06%
Previous 0.06%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$2.01 - $2.46 $43,214 - $52,890
21,500 Added 21.83%
120,000 $241,000
Q2 2024

Jul 31, 2024

BUY
$2.04 - $4.17 $200,940 - $410,745
98,500 New
98,500 $220,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $85.1M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Privium Fund Management B.V. Portfolio

Follow Privium Fund Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Privium Fund Management B.V. with notifications on news.